Float Short %

21.1

Margin Of Safety %

Put/Call OI Ratio

0.18

EPS Next Q Diff

0.45

EPS Last/This Y

1.57

EPS This/Next Y

1.53

Price

57.19

Target Price

76.25

Analyst Recom

1.25

Performance Q

33.23

Relative Volume

0.96

Beta

0.77

Ticker: TARS

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-07-28	TARS	41.76	3.07	999.99	1419
2025-07-29	TARS	40.21	3.08	0.04	1425
2025-07-30	TARS	40.02	2.89	0.00	1450
2025-07-31	TARS	38.82	2.54	0.15	1501
2025-08-01	TARS	40.99	2.56	999.99	1505
2025-08-04	TARS	41.9	2.57	0.33	1508
2025-08-05	TARS	41.14	2.57	117.17	1508
2025-08-06	TARS	41.69	4.19	90.82	2223
2025-08-07	TARS	47.92	6.41	0.24	3214
2025-08-08	TARS	47.8	5.76	0.57	3281
2025-08-11	TARS	50.07	5.74	0.08	3283
2025-08-12	TARS	51.36	4.81	5.00	3377
2025-08-13	TARS	52.7	4.78	0.02	3369
2025-08-14	TARS	54.15	4.73	0.08	3375
2025-08-15	TARS	54.22	4.63	0.00	3391
2025-08-18	TARS	54.65	0.12	0.00	561
2025-08-19	TARS	53.7	0.13	0.00	566
2025-08-20	TARS	55.46	0.12	1.59	570
2025-08-21	TARS	56.56	0.19	0.08	627
2025-08-22	TARS	57.24	0.18	0.22	678
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-07-28	TARS	41.58	50.5	-	-1.24
2025-07-29	TARS	40.14	57.0	-	-1.06
2025-07-30	TARS	40.00	57.0	-	-1.06
2025-07-31	TARS	38.82	57.0	-	-1.06
2025-08-01	TARS	40.81	57.0	-	-1.06
2025-08-04	TARS	41.91	57.0	-	-1.06
2025-08-05	TARS	41.15	57.0	-	-1.06
2025-08-06	TARS	41.66	57.0	-	-1.06
2025-08-07	TARS	47.95	57.0	-	-1.06
2025-08-08	TARS	47.85	80.3	-	-0.94
2025-08-11	TARS	50.07	80.3	-	-0.94
2025-08-12	TARS	51.36	44.7	-	-1.52
2025-08-13	TARS	52.72	44.7	-	-1.52
2025-08-14	TARS	54.17	44.7	-	-1.52
2025-08-15	TARS	54.21	42.6	-	-1.52
2025-08-18	TARS	54.57	42.6	-	-1.52
2025-08-19	TARS	53.70	42.2	-	-1.50
2025-08-20	TARS	55.47	42.2	-	-1.50
2025-08-21	TARS	56.55	42.2	-	-1.50
2025-08-22	TARS	57.19	42.2	-	-1.50
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-07-28	TARS	-2.61	9.57	21.46
2025-07-29	TARS	-2.61	9.57	21.46
2025-07-30	TARS	-2.61	9.57	21.46
2025-07-31	TARS	-2.61	9.57	21.46
2025-08-01	TARS	-2.61	9.57	21.46
2025-08-04	TARS	-2.61	8.21	21.46
2025-08-05	TARS	-2.61	8.21	21.46
2025-08-06	TARS	-2.61	8.21	21.46
2025-08-07	TARS	-2.61	8.21	21.46
2025-08-08	TARS	-2.61	8.21	21.46
2025-08-11	TARS	-2.59	8.09	21.35
2025-08-12	TARS	-2.59	8.09	21.17
2025-08-13	TARS	-2.74	8.09	21.17
2025-08-14	TARS	-2.74	8.09	21.17
2025-08-15	TARS	-2.74	8.09	21.17
2025-08-18	TARS	-2.74	8.92	21.10
2025-08-19	TARS	-2.84	8.92	21.10
2025-08-20	TARS	-2.84	8.92	21.10
2025-08-21	TARS	-2.84	8.92	21.10
2025-08-22	TARS	-2.84	8.92	21.10
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.48

Avg. EPS Est. Current Quarter

-0.35

Avg. EPS Est. Next Quarter

-0.03

Insider Transactions

-2.84

Institutional Transactions

8.92

Beta

0.77

Average Sales Estimate Current Quarter

113

Average Sales Estimate Next Quarter

131

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

10.2

Max Drawdown 5-Year %

Target Price

76.25

P/E

Forward P/E

58.85

PEG

P/S

8.18

P/B

7.27

P/Free Cash Flow

EPS

-2.33

Average EPS Est. Cur. Y

-1.5

EPS Next Y. (Est.)

0.03

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-31.13

Relative Volume

0.96

Return on Equity vs Sector %

-52.3

Return on Equity vs Industry %

-39.4

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.43

EBIT Estimation

Tarsus Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 323

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction. In addition, the company develops lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

stock quote shares TARS – Tarsus Pharmaceuticals Inc Stock Price stock today

news today TARS – Tarsus Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch TARS – Tarsus Pharmaceuticals Inc yahoo finance google finance

stock history TARS – Tarsus Pharmaceuticals Inc invest stock market

stock prices TARS premarket after hours

ticker TARS fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: TARS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y